Table 1 Patients characteristics

Age (years)

49 years [16–74]

Female

57 (57)

 b3a2

50 (50)

 b2a2

30 (30)

 b2a2 + b3a2

17 (17)

 b2a3

1 (1)

 Low risk < 0.8

35 (35)

 Intermediate risk 0.8–1.2

21 (21)

 High risk > 1.2

4 (4)

 Not available

40 (40)

Treatment

 Previously treated with interferon

32 (32)

 Frontline imatinib

43 (43)

 Frontline dasatinib

13 (13)

 Frontline nilotinib

9 (9)

 Frontline ponatinib

2 (2)

 Frontline bosutinib

1 (1)

 1 line

68 (68)

 ≥ 2 lines

32 (32)

 Imatinib

47 (47)

 Dasatinib

35 (35)

 Nilotinib

14 (14)

 Bosutinib

2 (2)

 Ponatinib

2 (2)

  < 10% (IS)

53 (95)

  ≥ 10% (IS)

3 (5)

 Duration (months) from start of TKI to CCyR

4 [2–78]

 Duration (months) from start of TKI to MMR

7 [1–91]

 Duration (months) from start of TKI to MR^4.5

17 [2–146]

Duration (months) from diagnosis to discontinuation

119 [11–403]

Duration (months) of last TKI before discontinuation

82 [1–198]

 Imatinib

121 [11–198]

 Dasatinib

64 [5–163]

 Nilotinib

71 [1–119]

 Bosutinib

47 [38–126]

 Ponatinib

15 [15–15]

Duration (months) of MR^4.5 before discontinuation

75 [1–178]

 < 2 years

11 (11)

 2 to 4 years

15 (15)

 4 to 6 years

20 (20)

 6 to 8 years

17 (17)

 8 to 10 years

20 (20)

  ≥10 years

17 (17)

 Adverse events

53 (53)

  Second cancer

2 (4)

 Elective

47 (47)

  Sustained MR^4.5

38 (84)

  Pregnancy

6 (13)

  Financial reasons

3 (7)

 Follow-up (months) after TKI discontinuation

30 [5–112]

 Loss of MR^4.5

35 (35)

 Loss of MMR

17 (17)

Retreatment

30 (30)

 MMR after retreatment

29 (97)

 MR^4.5 after retreatment

28 (93)

 Lost to follow-up after retreatment

1 (3)

 CCyR

2 (2)

 MMR

5 (5)

 MR^4.5

85 (85)

 Death

8 (8)^a